# Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00415818** · PHASE2,PHASE3 · COMPLETED · sponsor: **Transgene** · enrollment: 148 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** MVA-MUC1-IL2
- **DRUG:** 1st line Chemotherapy

## Key facts

- **NCT ID:** NCT00415818
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415818, "Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00415818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*